Drugs / JCXH-212
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05579275 | Feb 2023 → Apr 2026 overdue | cancer | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JCXH-212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05579275 ↗ |
| Action | Activate | “NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity” NCT05579275 ↗ |
| Modality | Messenger RNA (mRNA) | “a community-type tumor neoantigen mRNA vaccine” NCT05579275 ↗ |